중앙데일리

Samsung Bioepis begins research on Soliris biosimilar

Nov 01,2018
Korean pharmaceutical firm Samsung Bioepis has started research on a biosimilar for the drug Soliris, used to treat paroxysmal nocturnal hemoglobinuria (PNH), industry sources said Wednesday.

According to the sources, Samsung Bioepis plans to develop and release a more affordable version of the product - originally developed by U.S.-based Alexion Pharmaceuticals - under the name SB12.

Samsung Bioepis will carry out clinical tests on 240 adults in Germany. The project is estimated to run through April next year.

PNH is a disease in which the destruction of red blood cells leads to a red discoloration of the urine. Being a rare disease, there are only approximately 750 patients in Korea.

The local price of a single 30-milliliter (1 ounce) dose of Soliris costs 6 million won ($527). The average cost of the original is estimated at 500 million won for a one-year supply.

Samsung Bioepis said the latest move shows the company is penetrating the rare disease treatment drug market, based on its experiences in developing other biosimilar products.


Yonhap


dictionary dictionary | 프린트 메일로보내기 내블로그에 저장